share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3:募資說明書
美股sec公告 ·  05/22 22:14
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC announced the successful exercise of existing Series E and Series F warrants, resulting in approximately $7 million in gross proceeds. The exercised warrants, initially priced at $2.20, were exercised at a reduced price of $1.50 per American Depositary Share (ADS). The ADSs are registered under an effective registration statement (File No. 333-274895) filed with the SEC. In exchange for the cash exercise of the warrants, the warrant holders received new unregistered Replacement Warrants to purchase additional ADSs. The Replacement Warrants have an exercise price of $2.50 per ADS and terms of one and five years. The proceeds from the warrant exercises are intended to fund the company's clinical stage assets and for general corporate purposes. Additionally, the company has committed to...Show More
Biodexa Pharmaceuticals PLC announced the successful exercise of existing Series E and Series F warrants, resulting in approximately $7 million in gross proceeds. The exercised warrants, initially priced at $2.20, were exercised at a reduced price of $1.50 per American Depositary Share (ADS). The ADSs are registered under an effective registration statement (File No. 333-274895) filed with the SEC. In exchange for the cash exercise of the warrants, the warrant holders received new unregistered Replacement Warrants to purchase additional ADSs. The Replacement Warrants have an exercise price of $2.50 per ADS and terms of one and five years. The proceeds from the warrant exercises are intended to fund the company's clinical stage assets and for general corporate purposes. Additionally, the company has committed to filing a registration statement with the SEC for the resale of the ADSs issuable upon exercise of the Replacement Warrants. The announcement also included a press release detailing positive Phase 2 clinical trial results of Biodexa's eRapa in Familial Adenomatous Polyposis (FAP), showing a statistically significant decrease in overall mean polyp burden and an 83% non-progression rate at six months. The trial results are scheduled for presentation at the 2024 Digestive Disease Week annual meeting.
Biodexa Pharmicals PLC宣佈成功行使現有的E系列和F系列認股權證,總收益約爲700萬美元。行使的認股權證最初定價爲2.20美元,以每股美國存托股票(ADS)1.50美元的降價行使。ADS是根據向美國證券交易委員會提交的有效註冊聲明(文件編號333-274895)註冊的。爲了換取認股權證的現金行使,認股權證持有人獲得了新的未註冊替代認股權證,用於購買額外的ADS。替代認股權證的行使價爲每份ADS2.50美元,期限爲一年和五年。認股權證行使的收益旨在爲公司的臨床階段資產提供資金,並用於一般公司用途。此外,該公司已承諾向美國證券交易委員會提交註冊聲明,以轉售行使替代認股權證後可發行的美國存託憑證。該公告還包括一份新聞稿,詳細介紹了Biodexa的eRapa在家族性腺瘤性息肉病(FAP)中的2期臨床試驗的陽性結果,顯示總體平均息肉負擔在統計學上顯著下降,六個月的非進展率爲83%。試驗結果計劃在2024年消化系統疾病週年會上公佈。
Biodexa Pharmicals PLC宣佈成功行使現有的E系列和F系列認股權證,總收益約爲700萬美元。行使的認股權證最初定價爲2.20美元,以每股美國存托股票(ADS)1.50美元的降價行使。ADS是根據向美國證券交易委員會提交的有效註冊聲明(文件編號333-274895)註冊的。爲了換取認股權證的現金行使,認股權證持有人獲得了新的未註冊替代認股權證,用於購買額外的ADS。替代認股權證的行使價爲每份ADS2.50美元,期限爲一年和五年。認股權證行使的收益旨在爲公司的臨床階段資產提供資金,並用於一般公司用途。此外,該公司已承諾向美國證券交易委員會提交註冊聲明,以轉售行使替代認股權證後可發行的美國存託憑證。該公告還包括一份新聞稿,詳細介紹了Biodexa的eRapa在家族性腺瘤性息肉病(FAP)中的2期臨床試驗的陽性結果,顯示總體平均息肉負擔在統計學上顯著下降,六個月的非進展率爲83%。試驗結果計劃在2024年消化系統疾病週年會上公佈。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。